News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/radiotherapy-video-220.jpg)
CMT provides survival benefit in young HL patients
- Author:
- HT Staff
Combined modality therapy (CMT) can improve survival in young patients with early stage Hodgkin lymphoma (HL), according to research published in...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/daratumumab-230.jpg)
EC approves split dosing regimen for daratumumab
- Author:
- HT Staff
The European Commission (EC) has granted marketing authorization for a split dosing regimen for daratumumab (Darzalex®). The approval provides...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/red-blood-cells-240-imgarcade.jpg)
Potential treatment on the horizon for cold agglutinin disease
- Author:
- HT Staff
In a first-in-human trial, sutimlimab rapidly halted hemolysis, corrected anemia, precluded the need for transfusion, and caused no serious...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/pharmacist-vial-nci-danielsone-230.jpg)
FDA approves first treatment for BPDCN
- Author:
- HT Staff
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ultomiris-ravulizumab-businesswire-220.jpg)
FDA approves ravulizumab for PNH
- Author:
- HT Staff
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/vials_drug_Bill_Branson_230.jpg)
FDA approves calaspargase pegol-mknl for ALL
- Author:
- HT Staff
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg)
CHMP recommends treosulfan for allo-HSCT conditioning
- Author:
- HT Staff
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for treosulfan (Trecondi) as part...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/surgery_team_performing_Credit_Piotr_Bodzek_230.jpg)
CHMP backs lusutrombopag for severe thrombocytopenia
- Author:
- HT Staff
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for lusutrombopag to treat severe...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Polycythemia_vera_blood_smear_Credit_AFIP_230.jpg)
Long-acting interferon recommended for PV
- Author:
- HT Staff
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for ropeginterferon alfa-2b (...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ped_ALL_pt_receiving_chemo_Bill_Branson_230.jpg)
CHMP backs dasatinib for kids with newly diagnosed ALL
- Author:
- HT Staff
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/daratumumab-230.jpg)
Health Canada approves new indication for daratumumab
- Author:
- HT Staff
Health Canada has approved a third indication for daratumumab (Darzalex®) in multiple myeloma (MM). The drug is now approved for use in...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/brentuximab-vedotin-businesswire-230.png)
CHMP recommends BV+AVD for Hodgkin lymphoma
- Author:
- HT Staff
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/vials_drugs_Bill_Branson_230.jpg)
Romiplostim now approved for children with ITP
- Author:
- HT Staff
The thrombopoietin receptor agonist romiplostim (NPlate®) is now approved by the U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/enasidenib-IDHIFA-businesswire-230.jpg)
Serious side effect of AML treatment going unnoticed, FDA warns
- Author:
- HT Staff
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/gilteritinib-XOSPATA-220.jpg)
FDA approves gilteritinib for relapsed/refractory AML
- Author:
- HT Staff
The U.S.